Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors

In brief

Along with aging population, cancer incidence and mortality are increasing. However, despite advances in oncology and surgery, long-term survival of cancer patients is far from optimal. Dexmedetomidine is a highly selective alpha 2 adrenergic receptor agonist with sedative, analgesic, and anxiolytic effects. Studies showed that perioperative use of dexmedetomidine reduces delirium and some non-delirium complications after surgery. In long-term follow-up studies of older patients who, for other reasons, were randomized to receive either dexmedetomidine or placebo during intra- or postoperative period, dexmedetomidine use was associated with improved long-term survival. This multicenter randomized trial aims to investigate the effect of perioperative dexmedetomidine on long-term outcomes in older patients undergoing cancer surgery.

Key facts

Study ID

NCT06030804

Run by

Peking University First Hospital

People needed

4532

Starts

2023-09-12

Expected to finish

2028-10-01

Last updated by the study team

2025-07-31

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 60 years or older.
• Scheduled to undergo radical surgery for cancer under general anesthesia, with an expected surgical duration of 2 hours or longer.
• Required patient-controlled intravenous analgesia after surgery.

You may not qualify if…

• Inability to communicate preoperatively due to visual, auditory, verbal. or other reasons.
• Surgery for breast cancer or intracranial tumor.
• Preoperative severe sinus bradycardia (<50 beats per minute), sick sinus syndrome，or second-degree or above atrioventricular block without pacemaker.
• Severe hepatic dysfunction (Child-Pugh class C).
• Severe renal dysfunction (requirement of renal replacement therapy before surgery).
• Enrolled in other clinical studies.

Where it is running

• The First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (enrolling)
• The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) — Hefei, Anhui, China (enrolling)
• Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)
• Tsinghua University Yuquan Hospital — Beijing, Beijing Municipality, China (enrolling)
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (enrolling)
• The First Affiliated Hospital of Army Medical University (Southwest Hospital) — Chongqing, Chongqing Municipality, China (enrolling)
• Fujian Provincial Hospital — Fuzhou, Fujian, China (enrolling)
• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)
• Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
• Shanxi Cancer Hospital — Taiyuan, Shanxi, China (enrolling)
• Shanxi Provincial People's Hospital — Taiyuan, Shanxi, China (enrolling)
• Shanxi Bethune Hospital — Taiyuan, Shanxi, China (enrolling)
• First Affiliated Hospital of Xinjiang Medical University — Ürümqi, Xinjiang, China (enrolling)
• The First Affiliated Hospital of China University of Science and Technology — Hefei, Anhui, China (enrolling)
• Jinjiang City Hospital (Shanghai Sixth People's Hospital, Fujian Hospital) — Jinjiang, Fujian, China (enrolling)
• Guangdong General Hospital — Guangzhou, Guangdong, China (enrolling)
• Peking University Shenzhen Hospital — Shenzhen, Guangdong, China (enrolling)
• The First Affiliated Hospital of Shenzhen University — Shenzhen, Guangdong, China (enrolling)
• The Second Affiliated Hospital of Guangxi Medical University — Nanning, Guangxi, China (enrolling)
• Affiliated Cancer Hospital of Guangxi Medical University — Nanning, Guangxi, China (enrolling)
• The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
• The Second Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang, China (enrolling)
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (enrolling)
• Henan Provincial People's Hospital — Zhengzhou, Henan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.